Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
about
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaPhase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsPhase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsTanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction.Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaTargeting the 90 kDa heat shock protein improves photodynamic therapy.Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.In Vitro Activity of Geldanamycin Derivatives against Schistosoma japonicum and Brugia malayiStandard of care and promising new agents for triple negative metastatic breast cancerA phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaHeat shock protein 90 inhibition in lung cancer.A novel class of small molecule inhibitors of Hsp90.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trialsSynergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micellesPhase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.A highly invasive human glioblastoma pre-clinical model for testing therapeutics.Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesotheliomaHER2 breast cancer therapies: a reviewA phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerPhase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.Hsp90 as a therapeutic target in patients with oesophageal carcinoma.Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.(-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitorRole of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex.Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
P2860
Q28271726-174E9421-04BB-4BAB-A1C4-938F5020B5BEQ33387877-88F133E6-F910-46DE-983D-755C004EEE15Q33388351-775D6ADB-7BC5-4C9F-92BF-76BD8B74E189Q33390600-1E83C4F2-AA5A-442B-9AD0-9992E1730A0BQ33397124-2213FB62-E9D0-4C57-8991-3A9B40A3E689Q33408481-3742B075-55EA-4EC8-8297-1798276E7851Q33440318-FDD83483-1FD8-4A04-8617-9D2E2478507FQ33691235-A58553C3-6917-4456-8D4A-835E5AD2B7D7Q33836864-63A9BD3A-351C-4941-9066-90D33772A180Q34120364-44104266-CBF9-400B-98FE-D9D2C0BFC753Q34495415-159301A9-7482-4887-85F4-F255AD52CDE2Q34774884-9FD0C05B-43C6-40B7-81F8-92CB10964B4CQ35691439-3CC7A028-C235-4D10-8D4C-5B3425F8FD1EQ35762499-C598E102-ADE1-4F65-85D6-192B01214BA9Q35764444-5538971E-C389-4810-9447-7F114D5D57C3Q36162690-9028F972-82C9-454B-A5E0-335F06DC6025Q36493048-9195260C-66A5-437B-9C36-396F2A008F8FQ36501393-9A5B721C-E7BC-4058-BC1B-FE65A85231B4Q37068863-BC4EC301-0CA3-4C83-9AD4-B3C063F8C0A4Q37103825-FDC12913-EEB0-42E8-BCE6-F5E0BBD3964DQ37130217-39EE7C8A-B864-481E-8FB4-453227B466C3Q37303196-8BBA967E-865B-4413-9496-786392DC040DQ37338986-7B621219-6F26-4259-A8B3-1B6B187FA654Q37594553-6B51AC32-D4D6-4679-8F3B-4C9BADA84F14Q37635384-8AA4A008-F733-4048-AE42-B8ED95F44567Q37690758-88E759D3-43E6-4EFF-A875-CC73150A0D23Q37813152-61D97DEA-00F0-40ED-BBDC-146C86BF3F3FQ37827173-D4EB522D-EC43-4479-BC08-6539EF893A91Q39567800-4CE40A0B-8F9A-456A-BCB2-2FF2001055A4Q39676203-71E5C0A4-D257-401F-9BDE-C5F3AC3429BEQ39790544-E50CC52C-4C15-478D-9D9A-03EA593ECE26Q39900860-7F030091-02D9-4472-A176-462B83B9C01DQ41987459-CDC33F14-E62A-4468-8E57-27C12FC3F0B2Q51068076-AF234DDD-1E62-4CB8-8881-1FCE76F8D179
P2860
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@ast
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@en
type
label
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@ast
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@en
prefLabel
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@ast
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@en
P2093
P1476
Phase I and pharmacodynamic st ...... h refractory advanced cancers.
@en
P2093
Cynthia Naret
David Friedland
Douglas M Potter
Eleanor G Zuhowski
Gurkamal Chatta
Jianxia Guo
Julie L Eiseman
Merrill J Egorin
Ramesh K Ramanathan
Ronald G Stoller
P304
P356
10.1158/1078-0432.CCR-06-2233
P407
P577
2007-03-01T00:00:00Z